Gene Transfer Clinical Trial for Infantile and Late Infantile Krabbe Disease Treated Previously With HSCT

计划入组 9 人 · 首次发布于 2023 年 2 月 22 日

Gene Transfer Clinical Trial for Krabbe Disease

计划入组 6 人 · 首次发布于 2021 年 1 月 5 日

Galcanezumab for Vestibular Migraine

计划入组 40 人 · 首次发布于 2020 年 6 月 4 日

GALC gene therapy (AAV9, Krabbe disease)

allosteric GALC regulator program (Krabbe disease)

M-033

FUNDACION INSTITUTO DE INVESTIGACION SANITARIA DE SANTIAGO DE COMPOSTELA

Spain

PALC

France

GALA THERAPEUTICS INC

United States

Spatial Lipid Mapping Reveals Psychosine Buildup Patterns in Krabbe Disease, Opening New Therapeutic Targeting Strategies

Galcanezumab Shows Significant Promise in First Randomized Trial for Vestibular Migraine Treatment

Real-World Meta-Analysis Confirms Galcanezumab Efficacy in Migraine Prevention Across 3,859 Patients